Recombinant Human HLA-A*02:03&B2M&AFP(FMNKFIYEI) Monomer Protein (HEK293)，Avi & His

The study of the HLA-A*02:03/B2M/AFP (FMNKFIYEI) monomeric recombinant protein is situated at the intersection of immunology and cancer research. HLA-A*02:03 is a widely studied class I major histocompatibility complex (MHC) molecule, crucial for the presentation of endogenous peptides to CD8+ T cells, thereby playing a pivotal role in the adaptive immune response. The beta-2-microglobulin (B2M) component is essential for stable expression and function of the HLA-A molecules. Alpha-fetoprotein (AFP) is a tumor-associated antigen often overexpressed in hepatocellular carcinoma and other malignancies, making it an attractive target for immunotherapeutic approaches. By engineering a stable monomeric complex of HLA-A*02:03 with B2M and the AFP-derived peptide FMNKFIYEI, researchers aim to investigate the structural and binding characteristics of this particular antigenic presentation. This can provide insights into T cell recognition and activation, which is vital for developing targeted immunotherapies and enhancing vaccine efficacy against AFP-expressing tumors. Understanding the interactions within this complex can offer potential pathways for improving cancer immunotherapy strategies and contribute to personalized medicine approaches for patients with HLA-A*02:03 haplotypes. Through this research, the ultimate goal is to develop more effective and precise antigen-specific immunotherapies that leverage the body’s immune response against cancer.